Join Us Tomorrow! The Virtual Biopharma Comms Forum


Hi!

A quick reminder that our 2nd Annual Virtual Biopharma Comms Forum starts tomorrow, October 6th.

Over the next two half-days, we’ll gather virtually to explore what the expansion of the comms remit means for the profession, and how we as communicators can Own the Outcome (this year's forum theme).

Our agenda approaches this from multiple angles: From how the C-suite experiences comms counsel, to the changing boundaries of corporate affairs and measuring what matters to the business.

Sign up for Day 1 here, and Day 2 here.

DAY 1 | Tuesday, October 6th | 10:30 a.m.-1:45 p.m. ET

🕥 10:30 a.m. ET - Fireside Chat: How the C-Suite Experiences Communications Counsel
​
A CEO’s perspective on what makes comms counsel valuable at the highest levels of the business, with:

  • Jodie Morrison, CEO, Q32 Bio
  • José Juves, Chief Corporate & Patient Affairs Officer, Dyne Therapeutics

🕚 11 a.m. ET - Panel: Measuring What Matters to the Business
​
How communicators can move beyond outputs to demonstrate the outcomes and impact that matter to the business, with:

  • Brindha Dyer, JPMorgan Chase
  • Mark Hutcheon, Deloitte
  • Erin Patton, Denali Therapeutics
  • Jack O’Brien, MM+M (moderator)

🕛 12 p.m. ET - Workshop: Scoping Your First Agentic Workflow
​
Work through a real-world comms scenario to understand what it takes to scope and move an agentic workflow forward responsibly, facilitated by:

  • Skye King, Geode Lifeworks

​>>REGISTER FOR DAY 1​

DAY 2 | Wednesday, October 7th | 2-4 p.m. ET

🕑 2 p.m. ET - Welcome + Day 2 Opening Remarks

🕑 2:10 p.m. ET - Panel: The New Boundaries of Corporate Affairs
​
How the corporate affairs remit is evolving, and what that means for communicators working across increasingly interconnected disciplines, with:

  • Megan Humphreys, Evommune
  • Eric McKeeby, insitro
  • Bernadette Murdoch, CSL
  • Josh Deutchman, Wells Fargo (moderator)

🕒 3 p.m. ET - Case Study: How I Led Comms for a Record-Breaking Biotech IPO as a Fractional Leader
​
How a fractional communications leader built the strategy, infrastructure, and internal alignment needed to support an IPO, presented by:

  • Jessica Freifeld, JLF Strategy & Communications / Parabilis

🕞 3:30 p.m. ET - Case Study: Leading Communications Through Constant Flux With Agility, Influence, and Trust
​
An inside look at leading comms when priorities shift quickly, expectations evolve, and the path forward isn't necessarily clear, presented by:

  • Kim Fox, Legend Biotech

>>REGISTER FOR DAY 2​

T2B Pro and Student members can attend free as part of their membership. T2B Basic members can register for $275 per day.

You can join us for either days or both. Just remember that each day requires its own registration, so if you’re planning to attend both, make sure you’ve completed both forms.

I hope to see many of you on Zoom tomorrow!

Lynnea-

T2B Monthly

Read more from T2B Monthly

Hi! We spend a lot of time in comms planning for what we think is going to happen: building strategies, preparing for milestones, pressure-testing scenarios, and trying to anticipate what could change along the way. And then the plan changes. Or a scenario we didn't anticipate pops up. Sometimes it’s a small adjustment. Other times, a new development changes the people involved, the priorities, the timing, or the decision itself. The job becomes figuring out what still holds, what needs to...

T2B Monthly | September 2026 Hi! So appropriate that I'm finishing up this month's newsletter while I'm on a plane to San Diego, hosting our final mixer of Q3 tonight. Like I'm sure it's been for most of you, September has been go-go-go here at T2B! We celebrate this community's third(!!) anniversary in October, and it feels fitting that we're kicking off the month with our 2nd Annual Virtual Biopharma Comms Forum. This year's theme, Owning the Outcome, reflects so much of what we've been...

Hi! There's usually no shortage of data we have at our disposal as communicators. But what to focus on and signals stakeholder impact is often harder to identify. At next week's Virtual Biopharma Comms Forum, our panel “Measuring What Matters to the Business” will bring together perspectives from inside and outside comms to examine what credible evidence of impact looks like now, and how expectations are changing. Joining the conversation on Oct. 6th @ 11 a.m. ET: 💬 Brindha Dyer, Executive...